About Manisha Chatterjee
Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst.
Manisha’s goal is to help individual investors succeed in the stock market. She uses her knowledge in fundamental analysis to evaluate companies and determine if they are worthwhile investments.
Recent Articles By Manisha Chatterjee
Salesforce.com vs. Workday: Which SaaS Stock is a Better Buy?
Because the work-from-home trend is expected to continue even after the COVID-19 pandemic, and because many countries are witnessing second and third waves of coronavirus infections, we think Salesforce (CRM) and Workday (WDAY) should witness continued steady demand for their services over the coming months. But let’s find out which of these two stocks is a better buy now.
Nike: Buy the Dip?
Shares of Nike (NKE) plunged after the company announced mixed results for its fiscal 2021 third quarter. However, the company did manage to deliver solid growth when most companies in the footwear space were struggling amid the pandemic. And because NKE continues to take measures to accelerate sales growth through its digital channel, we think it is wise to buy the stock in the current price dip.
Should You Buy the Dip in Hims & Hers Health Stock?
Hims & Hers Health (HIMS) made its debut on the NYSE earlier this year after completing a reverse merger with blank-check company Oaktree Acquisition. However, the stock has fallen sharply since hitting its all-time high on February 8. Let’s discuss if the stock can recover based on its financials. Read on.
Monster Beverage: Buy, Sell, or Hold?
Monster Beverage (MNST) is one of the top names in the beverage industry, operating through various brands. But even though the company’s financials look solid, it faces intense competition from other industry leaders, such as PepsiCo (PEP) and Coca-Cola (KO). So, is it worth betting on the stock based on its financial strength? Let’s take a closer look.
Zomedica: Buy, Sell, or Hold?
Zomedica (ZOM), which develops diagnostic and pharmaceutical products for companion animals, saw little share price fluctuation over the past few years until the penny stock soared after being promoted on Netflix earlier this year. The stock has declined recently. So, the question is, can it regain its rally based on the sale of its Truforma diagnostic product ahead of schedule? Let’s find out.
Lizhi: An Electric Vehicle Supplier Stock Worth Buying?
The share price of Lizhi (LIZI) has been climbing quickly since the company went public in January 2020 thanks to huge demand for its in-car audio products. Given the company’s continued efforts to expand its market reach, we think it could be wise to bet on the stock now. Read on.
Up 160% in 2021, is ViacomCBS Still a Buy?
ViacomCBS (VIAC) managed to bounce back from its pandemic lows thanks to its strong financials and its launch of several new programs. However, can the launch of its subscription streaming service, Paramount Plus, differentiate the company from other service providers in a crowded streaming services space and bolster its fortunes? Let’s find out. Read on.
Is Seelos Therapeutics a Good Biotech Stock to Add to Your Portfolio?
Biopharmaceutical company Seelos Therapeutics (SEEL), which focuses on developing treatments for central nervous system and respiratory disorders, has a history of share price weakness. However, does the recent surge in its share price suggest a rebound for the company? Let’s find out. Read on.
Is Textron a Smart Long-Term Buy?
Multi-industry conglomerate Textron (TXT) was severely hit by a sharp decline in demand for its aviation products amid the COVID-19 pandemic. But it has recovered and has posted solid revenue growth across all its segments. As travel restrictions ease further, the company is expected to witness even greater demand for its products and services. So, we think it is wise to buy the stock now for solid gains in the long run. Let’s discuss the name.